The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Forbius
AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors.
 
Timothy A Yap
Consulting or Advisory Role - Aduro Biotech; Almac Diagnostics; AstraZeneca; Atrin Pharmaceuticals; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Cybrexa Therapeutics; EMD Serono; Ignyta; Janssen; Merck; Pfizer; Roche; Seagen; Tesaro; Vertex
Research Funding - AstraZeneca; Bayer; Constellation Pharmaceuticals; Jounce Therapeutics; Kyowa Hakko Kirin; Lilly; Pfizer; Seagen; Tesaro; Vertex
Patents, Royalties, Other Intellectual Property - MD Anderson Cancer Center holds the intellectual property rights to IACS-010759 and its designated use. (Inst)
Travel, Accommodations, Expenses - Atrin Pharmaceuticals; Calithera Biosciences; EMD Serono; Leidos Biomedical Research; Lilly; Pfizer; Tesaro
 
Nehal J. Lakhani
Consulting or Advisory Role - Innovent Biologics
Research Funding - Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Formation Biologics (Inst); Forty Seven (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Northern Biologics (Inst); Pfizer (Inst); Regeneron (Inst); Symphogen (Inst); TaiRx, Inc. (Inst); Tesaro (Inst)
 
Daniel Vilarim Araujo
Honoraria - BMS Brazil; GlaxoSmithKline; Libbs
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Bayer; Certara Inc; Certara Inc; Ellipses Pharma; iOncologi; Kelun; Merck Sharp & Dohme; Peptomyc; Pfizer; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bayer; Novartis
 
Sreenivasa R Chandana
Honoraria - HERON
Consulting or Advisory Role - Array BioPharma; Dicephera Pharmaceuticals, Inc.; HERON; IPSEN
Speakers' Bureau - Amgen; Eisai; IPSEN; Johnson & Johnson; Novartis
Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); ArQule (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Dicerna (Inst); Formation Biologics (Inst); Forty Seven (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst)
 
Manish Sharma
Research Funding - Alexo Therapeutics (Inst); Amgen (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Formation Biologics (Inst); Forty Seven (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); KLUS Pharma (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Northern Biologics (Inst); Pfizer (Inst); Regeneron (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); TaiRx, Inc. (Inst); Tesaro (Inst)
 
Jean-François Denis
Employment - Forbius
 
Tina Gruosso
Employment - Forbius
Research Funding - Forbius
 
Gilles Tremblay
Employment - Forbius
 
Maureen O'Connor
Employment - Forbius
 
Ria Ghosh
Employment - Forbius
 
Sandra Sinclair
No Relationships to Disclose
 
Debra L. Wood
Leadership - Forbius (I)
Consulting or Advisory Role - Forbius; Karyopharm Therapeutics (I); PRISM BioLab; Symphogen; Tessa Therapeutics
 
Paul I. Nadler
Leadership - Forbius
Consulting or Advisory Role - Forbius; Karyopharm Therapeutics; PRISM BioLab; Symphogen; Tessa Therapeutics
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Arvinas; AstraZeneca/MedImmune; GlaxoSmithKline; Loxo; Merck; Mirati Therapeutics; MorphoSys; Navire; Oncorus; Roche; Seagen; Symphogen; Treadwell Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)